Approximately 22% of Canadians aged 15 and older — about 6.2 million people — live with one or more disabilities, according to the most recent Canadian Survey on Disability (Statistics Canada). The disability community in Canada is not a single population but a constellation of overlapping experiences: physical disabilities, intellectual and developmental disabilities, sensory disabilities (Deaf, blind/low vision), chronic illnesses (multiple sclerosis, ME/CFS, fibromyalgia, Ehlers-Danlos syndromes), traumatic brain injury (TBI) and acquired brain injury (ABI), and autism spectrum experiences. Disability populations carry substantially elevated rates of depression, anxiety, PTSD, and chronic pain comorbidity — and yet have historically been under-represented in psychedelic-assisted therapy clinical trials, and often face physical, communication, and systemic accessibility barriers when seeking specialty mental health care. This article is a Canadian guide to what accessibility actually requires for psychedelic-assisted therapy: physical access, sensory accommodations, communication supports (ASL, LSQ, AAC, written communication), capacity-respecting consent processes, family and support involvement where appropriate, substance-specific medical considerations, and the honest framing that not all clinics are equally accessible — patients and families should ask before booking.

Key takeaways

~22% of Canadians (15+) have a disability per the Canadian Survey on Disability — physical, sensory, intellectual/developmental, chronic illness, TBI/ABI (traumatic or acquired brain injury), autism.

High mental health comorbidity — depression, anxiety, PTSD, chronic pain are substantially elevated in disability populations.

Accessibility is multi-dimensional — physical access (wheelchair, transfer support), sensory access (ASL/LSQ interpretation, written communication, tactile orientation), communication access (AAC, plain-language consent), cognitive access (capacity-supportive processes).

Sensory considerations during dosing matter — autistic patients and patients with sensory processing differences may experience heightened perceptual sensitivity; sound, lighting, and touch should be discussed in preparation.

Capacity to consent must be assessed individually — having an intellectual or developmental disability does not equal incapacity; capacity is decision-specific and supported decision-making is the appropriate framework.

Substance-specific medical considerations — cardiovascular conditions, hepatic and renal impairment, seizure disorders, mast cell disorders/EDS all require specific review.

Service animals must be accommodated — under the Accessible Canada Act and provincial human rights frameworks.

Coverage pathways exist — CPP-D, ODSP, BC PWD, AISH, Quebec disability programs, private LTD, VAC, WSIB/WCB depending on circumstance.

Not all clinics are equally accessible — patients and families should ask specific questions before booking.

ATMA CENA's commitment to accessibility is concrete: intake-call accommodations, clinic accessibility audit, communication-preference documentation, family/support inclusion where the patient consents.

The Canadian disability landscape

The Canadian Survey on Disability (CSD) — Statistics Canada's flagship disability data instrument — uses the Disability Screening Questions (DSQ) to identify disability across ten domains: seeing, hearing, mobility, flexibility, dexterity, pain, learning, developmental, mental health-related, and memory. The 2022 CSD reported 27% of Canadians aged 15+ had at least one disability (up from 22% in 2017), with the most common types being pain-related, flexibility, mobility, and mental health-related. Disability prevalence rises substantially with age — over 40% in adults 65+.

Disability in Canada is framed legislatively by the Accessible Canada Act (ACA, 2019) at the federal level, and by provincial legislation including the Accessibility for Ontarians with Disabilities Act (AODA), the Accessible British Columbia Act, the Accessibility Act (Manitoba), the Nova Scotia Accessibility Act, and corresponding frameworks in other provinces. The WHO International Classification of Functioning, Disability and Health (ICF) provides the biopsychosocial model that Canadian rehabilitation medicine generally operates within — disability is not a property of the individual alone but of the interaction between body, activity, participation, and environment.

For psychedelic-assisted therapy, this means: accessibility is a clinic responsibility, not a patient responsibility.

Mental health comorbidity in disability populations

Mental health need is substantially elevated across disability populations:

Depression: prevalence in adults with disabilities is roughly 2–3× the general population; in chronic illness populations (MS, ME/CFS, fibromyalgia, EDS) it is higher still
Anxiety: similarly elevated; chronic illness uncertainty, ableism, and isolation contribute
PTSD: elevated in TBI/ABI populations, in adults with intellectual/developmental disabilities (high lifetime trauma exposure rates), and in chronic illness populations with medical trauma histories
Chronic pain comorbidity: frequently co-occurs across disability populations — covered substantively in Chronic Pain and Psychedelic-Assisted Therapy
Suicide risk: elevated in several disability populations — including autistic adults, adults with chronic pain, and adults with acquired physical disability

Treatment gaps are also substantial. Canadians with disabilities report higher unmet mental health need than the general population — driven by physical inaccessibility of clinics, communication barriers, financial barriers, ableism in clinical encounters, and a smaller pool of clinicians who advertise disability-affirming practice.

Physical accessibility — the foundation

Physical access is the most visible — and most variable — accessibility dimension. For psychedelic-assisted therapy specifically:

Wheelchair accessibility of the clinic entrance, washroom, dosing room, and any monitoring spaces
Transfer support — for patients who require assistance moving from wheelchair to dosing chair/recliner; appropriate equipment (transfer board, ceiling lift in some settings) and trained staff
Adaptive equipment — adjustable recliners, pressure relief surfaces for patients with pressure injury risk, supportive positioning aids
Bariatric considerations — equipment rated for higher weight capacity
Accessible washrooms — grab bars, sufficient turning radius, height-appropriate fixtures
Parking and drop-off — accessible parking near the entrance, sheltered drop-off where possible
Clinic accessibility audit — clinics committed to accessibility commission third-party audits and publish results

ATMA CENA's commitment includes a clinic accessibility audit and willingness to discuss specific physical access needs at the intake-call stage. Patients and families should ask specific questions: not "is your clinic accessible?" but "what is the door width on the dosing room? Is there a height-adjustable recliner? Is there transfer assistance available?"

Sensory disabilities — Deaf, hard of hearing, blind, and low vision

Deaf and hard-of-hearing patients

Communication accessibility is the central variable for Deaf and hard-of-hearing patients in psychedelic-assisted therapy:

ASL (American Sign Language) interpretation — for Anglophone Deaf patients. Mental health interpretation is a specialty; not all interpreters are trained in mental-health-specific vocabulary and confidentiality frameworks. Booking a qualified mental health interpreter for preparation, dosing day, and integration sessions is the standard.
LSQ (Langue des signes québécoise) — for Francophone Deaf patients in Quebec and elsewhere; LSQ is a distinct language from ASL.
Written communication and CART (Communication Access Realtime Translation) — for many hard-of-hearing patients who do not use sign language
Visual ASL preparation materials — preparation videos in ASL, not English subtitles on hearing-targeted videos
Accommodations during dosing — the dosing experience involves altered states; communication must be planned in advance. Visual signal systems, designated check-in moments, written boards, and pre-arranged interpreter presence (with understanding of confidentiality) should all be discussed during preparation
Lighting for visual communication — sufficient ambient lighting for sign language to be received during sessions

The Canadian Hearing Services and Canadian Association of the Deaf are useful resource organizations for patients and clinics.

Blind and low-vision patients

Orientation to the clinic — pre-visit orientation, tactile maps, guided walk-through; sighted-guide training for staff
Tactile preparation materials — Braille handouts where requested; audio versions of written materials
Screen-reader-compatible online materials — clinic websites and intake forms must work with JAWS, NVDA, and VoiceOver
Service animals — guide dogs are protected; clinics must accommodate (see service animals section below)
Sensory considerations during dosing — patients using touch and sound as primary perceptual channels may experience the psychedelic state differently; preparation should reflect this

Autism spectrum and sensory processing

Autistic Canadians are a substantial population — Public Health Agency of Canada estimates roughly 1 in 50 children are diagnosed with autism, with rising adult identification. Mental health comorbidity is high — anxiety disorders, depression, OCD, and PTSD are all substantially elevated. Suicide risk is elevated in autistic adults, particularly those without intellectual disability.

For psychedelic-assisted therapy with autistic patients:

Sensory considerations during dosing are central — many autistic patients have heightened or atypical sensory processing (sound, lighting, touch, smell). The standard "psychedelic set and setting" of dim lighting, eye masks, curated music, and hand-on-shoulder touch points may not be optimal — and may be distressing — for some autistic patients. Sensory profile assessment during preparation and individualized dosing-room setup are appropriate.
Preparation phase is critical — many autistic patients benefit from extensive structured preparation: written agendas, visual schedules, predictable session format, pre-session walk-through of the dosing room, explicit naming of expected sensations and timeline.
Communication style — direct, literal, structured communication often works better than open-ended exploratory questioning. Plain language and explicit framing of decisions support consent.
Touch protocols — the question of whether a hand on the shoulder is grounding or distressing varies; consent for touch should be explicit and revisitable.
Pre-existing autism-specific medications (stimulants, SSRIs, antipsychotics, sleep medications) should be reviewed for interactions
Integration support — structured, concrete integration is often more accessible than purely process-oriented integration

The emerging psychedelic-and-autism research base — including the MAPS-affiliated MDMA-assisted therapy for social anxiety in autistic adults pilot (Danforth et al. 2018) — is small but signals that autistic patients can engage successfully with psychedelic-assisted therapy when accommodations are made. Generalization is limited and outcome promises are not warranted.

Intellectual and developmental disabilities

Adults with intellectual and developmental disabilities (IDD) carry substantially elevated rates of mental health comorbidity and substantially higher unmet mental health need than the general population. Considerations:

Capacity to consent must be assessed individually and decision-specifically — having an intellectual or developmental disability does not equal incapacity. Canadian consent frameworks (e.g., Ontario Health Care Consent Act, Quebec Civil Code, BC Health Care (Consent) and Care Facility (Admission) Act) require decision-specific capacity assessment for the proposed intervention.
Supported decision-making is the appropriate framework in many cases — accessible explanation, plain-language materials, time, and involvement of trusted supporters during the decision process. Substitute decision-making is a last resort and is constrained by provincial frameworks.
Comprehensive informed consent assessment — for psychedelic-assisted therapy specifically, capacity must encompass understanding of the altered state, the possibility of distressing experiences, monitoring requirements, and the integration phase.
Family and support involvement — where the patient consents, family or support workers involved in preparation and integration can be clinically meaningful. This is the patient's choice, not the family's choice.
Communication accessibility — plain-language materials, visual supports, repeated explanation, written summaries
Pre-existing medications — including antipsychotics, mood stabilizers, anticonvulsants — must be reviewed for interactions
Honest framing — for some patients with IDD, psychedelic-assisted therapy will not be appropriate; that is a clinically valid outcome and not a failure

The Canadian Association for Community Living (Inclusion Canada) and provincial frameworks for adults with IDD provide useful policy context.

TBI/ABI and cognitive disabilities

Traumatic brain injury and acquired brain injury (post-stroke, anoxic, neurosurgical) populations frequently carry depression, anxiety, PTSD, and cognitive difficulties. Specific considerations:

Cognitive considerations during preparation and integration — pacing, written summaries, repeated explanation, simplified materials where helpful
Medication interactions — anticonvulsants (often present after TBI), stimulants, antidepressants — all require review
Seizure history — a substantial subset of TBI patients have post-traumatic epilepsy. Seizure disorders shift the risk profile (see seizure section below).
Cardiovascular considerations — particularly for stroke survivors
Cognitive screening — pre-treatment cognitive baseline can inform integration planning
Concussion history is common in disability populations broadly and should be elicited

Substance-specific medical considerations

Cardiovascular conditions

Ketamine and esketamine produce acute increases in blood pressure and heart rate. The Spravato product monograph specifies BP monitoring; uncontrolled hypertension is a contraindication. Patients with cardiovascular comorbidity, including stable hypertension, ischemic heart disease, arrhythmias, and aortic disease, require explicit assessment.
Psilocybin produces sympathomimetic load — modest BP/HR elevation.
MDMA produces substantial cardiovascular load across the dosing window; significant cardiovascular disease is typically an exclusion in MDMA RCTs.
Patients with dysautonomia (common in EDS, ME/CFS, post-COVID) require specific consideration — POTS and orthostatic intolerance interact with the cardiovascular load of these substances.

Hepatic and renal impairment

Ketamine is hepatically metabolized (CYP3A4, CYP2B6) to norketamine. Hepatic impairment affects clearance; dosing adjustments and extended monitoring may be required.
Renal function affects elimination; eGFR should be reviewed.
Psilocybin is hepatically dephosphorylated to psilocin and conjugated; hepatic considerations apply.
Disability populations with chronic liver or kidney involvement (including some forms of MS treatment-related hepatic effects, NSAID-related renal effects in chronic pain, and primary hepatic/renal disease) require explicit review.

Seizure disorders

Ketamine has a complex relationship with seizure activity — it has been used in refractory status epilepticus and is generally not considered pro-convulsant at sub-anesthetic doses, but individual review with neurology is warranted in patients with active seizure disorders.
Psilocybin and MDMA have less established seizure risk profiles; most RCTs have excluded patients with active seizure disorders.
Patients with post-traumatic epilepsy, idiopathic epilepsy, or seizures secondary to other neurological conditions should have neurology review before psychedelic-assisted therapy.
Anticonvulsant interactions — many anticonvulsants are CYP inducers/inhibitors with relevant interaction profiles.

Mast cell disorders and Ehlers-Danlos syndromes

There is emerging awareness of mast cell activation syndrome (MCAS) and hypermobile Ehlers-Danlos syndrome (hEDS) — including their frequent co-occurrence with POTS, ME/CFS, and chronic pain. These populations frequently report medication sensitivity — atypical responses to standard doses, paradoxical reactions, and elevated rates of medication intolerance. For psychedelic-assisted therapy:

Cautious dosing with attention to patient self-report
Antihistamine and mast-cell-stabilizer medication regimens should be reviewed for interactions
Cardiovascular considerations are amplified in dysautonomia patients
Connective tissue considerations — positioning, support during dosing, joint protection during any restraint or repositioning

The evidence base is small; honest framing is appropriate.

Sensory processing in the psychedelic experience

The "set and setting" of a standard psychedelic dosing session — eye mask, curated music, low ambient lighting, occasional grounding touch — is a clinical heuristic, not a universal optimum. For patients with autism, sensory processing differences, sensory disabilities, or chronic pain conditions with sensory amplification (fibromyalgia, central sensitization), this default may not work and may be actively harmful.

Individualized sensory planning is the appropriate response:

Music: patient-curated, instrumental vs vocal, familiar vs unfamiliar
Lighting: dim vs ambient; eye mask optional; some patients require visual openness
Touch: explicit consent for any contact; pre-defined signals; opt-in not opt-out
Sound environment: noise-cancelling headphones, white noise, quiet room considerations
Temperature and weighted blankets: comfort items as appropriate
Companion presence: support person presence as the patient prefers

Service animals

Service animals — including guide dogs for blind patients, hearing dogs, mobility service dogs, psychiatric service dogs, and seizure-alert dogs — are protected under the Accessible Canada Act and provincial human rights frameworks. Clinics must accommodate service animals. Practical considerations:

Accommodations during dosing — the service animal's presence during the session, where the patient prefers, is supported
Animal welfare — long sessions require appropriate breaks for the animal; planning is part of preparation
Allergen and infection control — rare but possible accommodations in shared clinic spaces
Distinction from emotional support animals — provincial frameworks vary; clinics should be transparent about their policies in advance

Communication aids — AAC

Augmentative and alternative communication (AAC) — ranging from picture symbols to text-based devices to eye-gaze systems — is used by Canadians across multiple disability populations including cerebral palsy, ALS, severe autism, post-stroke aphasia, and others. For psychedelic-assisted therapy:

AAC use during preparation, dosing, and integration must be explicitly planned
Device positioning during dosing — physical access and visual access to the device
Speech-language pathology involvement in consent and communication planning may be appropriate
Alternative response systems — for moments when AAC use is impractical, pre-arranged signal systems

Caregiver and family involvement

Family and support involvement varies enormously across disability populations and across individual patients. The patient's preference is the determining variable. Considerations:

Capacity-respecting framework — for adults with capacity, family involvement is at patient discretion. Family preference does not override patient preference.
Substitute decision-makers — for adults assessed as lacking capacity for the specific decision, provincial substitute-decision-maker frameworks apply; psychedelic-assisted therapy is a high-bar intervention and many provincial frameworks may not authorize substitute consent for it
Family presence at preparation and integration — frequently clinically meaningful where the patient wants it
Family presence on dosing day — varies by clinic and substance; some settings welcome it, some restrict it
Caregiver mental health — caregivers themselves often carry depression, anxiety, and burnout; clinical recognition matters

For more detail on family and loved ones, see Family Members and Loved Ones — A Guide.

Coverage pathways for disability

Federal — CPP-D and the Canada Disability Benefit

Canada Pension Plan Disability (CPP-D) — federal disability income for those with sufficient CPP contributions. CPP-D itself does not cover medical treatment costs — but eligibility may correlate with private insurance LTD coverage.
Canada Disability Benefit (CDB) — newer federal income benefit (2024 onward) for working-age Canadians with disabilities; income support, not medical coverage.

Provincial disability programs

Ontario Disability Support Program (ODSP) — income and limited extended health (drug coverage via ODB; some medical supplies). ODSP recipients have Trillium Drug Program / Ontario Drug Benefit pathways for Spravato (rare). Out-of-pocket ketamine and SAP psilocybin costs are typically not ODSP-covered.
BC Persons with Disabilities (PWD) — income and BC PharmaCare access; Spravato through PharmaCare Plan W or special authority pathways.
Alberta Assured Income for the Severely Handicapped (AISH) — income and Alberta Blue Cross access for some medications; Spravato pathways through provincial drug programs.
Quebec disability programs — Programme de solidarité sociale (severely limited capacity for employment) and RAMQ public drug plan; Farzin/Stephan precedent (December 2022) establishes a RAMQ exception pathway for SAP psilocybin in end-of-life distress.

Private long-term disability (LTD)

Private LTD insurance (Manulife, Sun Life, Canada Life, Desjardins, others) — disability income, sometimes with associated extended health coverage. Spravato prior-authorization pathways are well-established with major carriers; off-label ketamine and SAP psilocybin coverage is rare but case-by-case requests are not unprecedented.
For more detail, see Insurance Coverage for Psychedelic-Assisted Therapy in Canada.

VAC for service-related disability

Veterans Affairs Canada has an established case-by-case pathway for psychedelic-assisted therapy (predominantly ketamine; some SAP psilocybin) for service-related conditions including PTSD and depression. Veterans with disability-related mental health conditions should explore this pathway.
For more detail, see VAC Coverage for Psychedelic-Assisted Therapy.

WSIB / WCB for compensable conditions

Provincial workers' compensation boards (WSIB Ontario, WorkSafeBC, WCB Alberta, CNESST Quebec, others) cover treatment for compensable injuries — and a subset of disabled workers carry compensable claims for which psychedelic-assisted therapy may be considered case-by-case (most commonly ketamine for chronic pain or PTSD).
For more detail, see Workers' Compensation and Psychedelic-Assisted Therapy.

ATMA CENA's commitment to accessibility

ATMA CENA's accessibility-specific actions:

Intake-call accommodations: communication preferences identified at first contact — ASL/LSQ interpreter booking, written-only intake, AAC-compatible workflows, accessible scheduling tools
Clinic accessibility audit: physical accessibility documented and willing to be discussed in detail
Communication-preference documentation: the patient's communication accommodations travel with them across preparation, dosing, and integration phases
Family/support inclusion at the patient's discretion, in writing
Sensory profile assessment during preparation for autistic patients and patients with sensory processing differences
Service animal accommodation as a clinic baseline
Coordinated care alongside specialty disability care — neurology, physiatry, rehabilitation, palliative care, mental health teams already in place
Honest framing: not all patients are appropriate candidates after assessment — and a clear "not now" or "not at all" outcome is part of accessible care

What this article does NOT promise

No outcome promises. Psychedelic-assisted therapy is investigational for most indications; SAP-pathway access is case-by-case.
No claim that all clinics are equally accessible — they are not. Asking specific questions before booking is the patient's and family's appropriate role.
No claim that disability-specific RCT evidence is robust — it is not. The autism-and-MDMA pilot literature is small. Generalization from broader RCT populations to disability-specific populations should be made carefully.
No substitute decision-making for adults with capacity — capacity is decision-specific, presumed in adults, and supported wherever possible.
No SAP shortcuts — the SAP pathway is a real, slow, case-by-case Health Canada process regardless of disability status.

Frequently asked questions

Is the clinic wheelchair-accessible? Ask specifically: door widths, dosing-room layout, washroom accessibility, transfer support. A general "yes" is not sufficient.

Can I bring an ASL or LSQ interpreter? Yes — qualified mental-health interpreters should be booked for preparation, dosing, and integration sessions. The clinic should be experienced in working with interpreters and confidentiality frameworks.

I'm autistic and worried about sensory overload during dosing — can the setup be customized? Yes. Sensory profile assessment during preparation, individualized dosing-room setup (lighting, sound, touch, eye-mask use), and explicit communication about expectations are part of accessible practice.

I have an intellectual disability — can I still consent? Capacity is decision-specific and presumed in adults. Supported decision-making — accessible explanation, time, plain-language materials, involvement of trusted supporters with your consent — is the appropriate framework. A diagnosis of IDD does not equal incapacity.

My family member has a brain injury and seizures — is this safe? This requires individualized review with neurology. Active seizure disorders shift the risk profile and most psilocybin/MDMA RCTs have excluded patients with active seizure disorders. Ketamine has a more complex seizure-relationship profile and may be considered with neurology review.

I have EDS and chronic pain — does that disqualify me? Not automatically. EDS, MCAS, POTS, and dysautonomia populations are recognized as having medication sensitivity considerations and dysautonomia-related cardiovascular considerations. Cautious dosing and explicit medical review are appropriate.

Can my service dog be with me during dosing? Yes — service animals are protected and accommodated. The animal's welfare across the session is part of preparation planning.

I use AAC — can I still participate? Yes. AAC use during preparation, dosing, and integration must be explicitly planned — device positioning, alternative signal systems for moments when AAC is impractical, and SLP involvement where appropriate.

Can my family be present? At your preference. Family/support involvement during preparation and integration is frequently clinically meaningful where the patient wants it; dosing-day presence varies by clinic and substance.

Will CPP-D or ODSP cover the cost? CPP-D and most provincial disability income programs do not directly cover psychedelic-assisted therapy. Spravato has prior-authorization pathways through provincial drug plans and private LTD insurers. Off-label ketamine and SAP psilocybin are typically out-of-pocket for disability-program recipients, with VAC, WSIB/WCB, and case-by-case private LTD pathways as exceptions.

My disability is service-related — does VAC cover this? For veterans with service-related conditions, VAC has an established case-by-case pathway. See the VAC coverage hub for detail.

My disability resulted from a workplace injury — does WSIB/WCB cover this? Compensable conditions can be considered case-by-case by provincial workers' compensation boards, most commonly for chronic pain and PTSD pathways involving ketamine.

Are all clinics equally accessible? No. Patients and families should ask specific questions about physical access, communication access, sensory accommodations, service animal policy, and family inclusion before booking.

Sources

Statistics Canada — Canadian Survey on Disability, 2022: https://www150.statcan.gc.ca/n1/daily-quotidien/231201/dq231201b-eng.htm
Government of Canada — Accessible Canada Act (2019): https://laws-lois.justice.gc.ca/eng/acts/A-0.6/
Government of Ontario — Accessibility for Ontarians with Disabilities Act (AODA): https://www.aoda.ca/the-act/
World Health Organization — International Classification of Functioning, Disability and Health (ICF): https://www.who.int/classifications/international-classification-of-functioning-disability-and-health
Public Health Agency of Canada — Autism Spectrum Disorder Among Children and Youth in Canada: https://www.canada.ca/en/public-health/services/publications/diseases-conditions/autism-spectrum-disorder-children-youth-canada-2018.html
Autism Canada / Autism Society Canada: https://autismcanada.org/
Danforth AL, Grob CS, Struble C, et al. (2018). Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: a randomized, double-blind, placebo-controlled pilot study. Psychopharmacology, 235(11):3137-3148. PMID: 30196397.
Health Canada — Special Access Program: https://www.canada.ca/en/health-canada/services/drugs-health-products/special-access.html
Health Canada — Spravato Product Monograph: https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98903
Inclusion Canada (formerly Canadian Association for Community Living): https://inclusioncanada.ca/
Government of Canada — Canada Disability Benefit: https://www.canada.ca/en/services/benefits/disability/canada-disability-benefit.html
Service Canada — Canada Pension Plan Disability Benefits: https://www.canada.ca/en/services/benefits/publicpensions/cpp/cpp-disability-benefit.html
Ontario Ministry of Children, Community and Social Services — ODSP: https://www.ontario.ca/page/ontario-disability-support-program
Canadian Hearing Services / Canadian Association of the Deaf — disability community resource organizations.

Older Adults and Psychedelic-Assisted Therapy — overlapping disability prevalence in 65+ population
Chronic Pain and Psychedelic-Assisted Therapy — frequent disability comorbidity
Family Members and Loved Ones — A Guide
VAC Coverage for Psychedelic-Assisted Therapy
Workers' Compensation and Psychedelic-Assisted Therapy
Insurance Coverage for Psychedelic-Assisted Therapy in Canada
Psilocybin Therapy in Canada
Ketamine Therapy in Canada
MDMA-Assisted Therapy in Canada

Last updated: 2026-05-06

People with Disabilities and Psychedelic-Assisted Therapy in Canada — Accessibility and Considerations

Access and legality vary by jurisdiction